17 . October , 2018 - Wednesday
Check todays hot topics or new products

Find a Drug: Advanced

Please Sign in or Register

All about: Ergoloid

Big Image
Generic Name: Ergoloid mesylates
Dosage Form: Sublingual tablets

Ergoloid Description

Each tablet for sublingual use contains 1 mg of Ergoloid Mesylates USP, a mixture of the methanesulfonate salt of the following hydrogenated alkaloids: Dihydroergocornine mesylate 0.333 mg Dihydroergocristine mesylate 0.333 mg Dihydroergocryptine mesylate*1 0.333 mg

Ergoloid mesylates tablets, USP for sublingual use contain the following inactive ingredients: anhydrous lactose, colloidal silicon dioxide, microcrystalline cellulose, pregelatinized starch, and stearic acid.

* Exists as a mixture of alpha and beta isomers in a ratio of 2:1

Ergoloid - Clinical Pharmacology

There is no specific evidence which clearly establishes the mechanism by which Ergoloid mesylates tablets produce mental effects, nor is there conclusive evidence that the drug particularly affects cerebral arteriosclerosis or cerebrovascular insufficiency.

Pharmacokinetic Properties

Pharmacokinetic studies have been performed in normal volunteers with the help of radio-labelled drug as well as employing a specific radioimmunoassay technique. From the urinary excretion quotient of orally and intravenously administered tritium-labelled Ergoloid mesylates the absorption of Ergoloid was calculated to be 25%. Following oral administration, peak levels of 0.5 ng Eq/mL/mg were achieved within 1.5-3 hrs. Bioavailability studies with the specific radio-immunoassay confirm that Ergoloid is rapidly absorbed from the gastrointestinal tract, with mean peak levels of 0.05-0.13 ng/mL/mg (with extremes of 0.03 and 0.18 ng/mL/mg) achieved within 0.6-1.3 hr. (with extremes of 0.4 and 2.8 hrs.). The finding of lower peak levels of Ergoloid compared to the total drug-metabolite composite is consistent with a considerable first pass liver metabolism, with less than 50% of the therapeutic moiety reaching the systemic circulation. The elimination of radioactivity, representing Ergoloid plus metabolites bearing the radiolabel, was biphasic with half-lives of 4 and 13 hr. The mean half-life of unchanged Ergoloid in plasma is about 2.6-5.1 hr; after 3 half-lives Ergoloid plasma levels are less than 10% of radioactivity levels, and by 24 hr. no Ergoloid is detectable. Bioavailability studies were performed comparing Ergoloid mesylates oral tablets (administered orally) with Ergoloid mesylates sublingual tablets (administered sublingually). The oral tablet and sublingual tablet were shown to have similar bioavailability.

Indications and Usage for Ergoloid

A proportion of individuals over sixty who manifest signs and symptoms of an idiopathic decline in mental capacity (i.e., cognitive and interpersonal skills, mood, self-care, apparent motivation) can experience some symptomatic relief upon treatment with Ergoloid mesylates preparations. The identity of the specific trait(s) or condition(s), if any, which would usefully predict a response to Ergoloid mesylates therapy is not known. It appears, however, that those individuals who do respond come from groups of patients who would be considered clinically to suffer from some ill-defined process related to aging or to have some underlying dementing condition (i.e., primary progressive dementia, Alzheimer’s dementia, senile onset, multi-infarct dementia). Before prescribing Ergoloid mesylates therapy, the physician should exclude the possibility that the patient’s signs and symptoms arise from a potentially reversible and treatable condition. Particular care should be taken to exclude delirium and dementiform illness secondary to systemic disease, primary neurological disease or primary disturbance of mood.

Ergoloid mesylates preparations are not indicated in the treatment of acute or chronic psychosis, regardless of etiology (see CONTRAINDICATIONS section). The decision to use Ergoloid mesylates therapy in the treatment of an individual with a symptomatic decline in mental capacity of unknown etiology should be continually reviewed since the presenting clinical picture may subsequently evolve sufficiently to allow a specific diagnosis and a specific alternative treatment. In addition, continued clinical evaluation is required to determine whether any initial benefit conferred by Ergoloid mesylates therapy persists with time.

The efficacy of Ergoloid mesylates therapy was evaluated using a special rating scale known as the SCAG (Sandoz-Clinical Assessment Geriatric). The specific items on this scale on which modest but statistically significant changes were observed at the end of twelve weeks include: mental alertness, confusion, recent memory, orientation, emotional lability, self-care, depression, anxiety/fears, cooperation, sociability, appetite, dizziness, fatigue, bothersome(ness), and an overall impression of clinical status.


Ergoloid mesylates tablets are contraindicated in individuals who have previously shown hypersensitivity to the drug. Ergoloid mesylates preparations are also contraindicated in patients who have psychosis, acute or chronic, regardless of etiology.


Practitioners are advised that because the target symptoms are of unknown etiology carefuI diagnosis should be attempted before prescribing Ergoloid mesylates tablets.

Adverse Reactions

Ergoloid mesylates tablets have not been found to produce serious side effects. Some sublingual irritation with the sublingual tablets, transient nausea, and gastric disturbances have been reported. Ergoloid mesylates preparations do not possess the vasoconstrictor properties of the natural ergot alkaloids.

Ergoloid Dosage and Administration

1 mg three times a day. Alleviation of symptoms is usually gradual and results may not be observed for 3-4 weeks.

How is Ergoloid Supplied

Available as oval, white sublingual tablets, debossed 2959, containing 1 mg Ergoloid mesylates USP, packaged in bottles of 100, 250 and 1000 tablets.

PHARMACIST: Dispense in a tight, light-resistant container as defined in the USP. Use child-resistant closure (as required).

Store at controlled room temperature 15°-30°C (59°-86°F) (See USP).



MIAMI, FL 33137




Ergoloid Mesylates (Ergoloid Mesylates)
Product Code 0172-2959 Dosage Form TABLET, ORALLY DISINTEGRATING
Route Of Administration ORAL DEA Schedule
Name (Active Moiety) Type Strength
Ergoloid Mesylates (Ergoloid Freebase) Active 1 MILLIGRAM  In 1 TABLET
anhydrous lactose Inactive  
colloidal silicon dioxide Inactive  
microcrystalline cellulose Inactive  
pregelatinized starch Inactive  
stearic acid Inactive  
Characteristic Appearance Characteristic Appearance
Color WHITE Score 1
Shape OVAL Symbol false
Imprint Code 2959 Coating false
Size 11mm
# NDC Package Description Multilevel Packaging
1 0172-2959-60 100 TABLET In 1 BOTTLE None
2 0172-2959-65 250 TABLET In 1 BOTTLE None
3 0172-2959-80 1000 TABLET In 1 BOTTLE None

Revised: 03/2007

Recent Drug Updates at DrugIndexOnline:

atenolol and chlorthalidone atenolol and chlorthalidone
Generic Name: atenolol and chlorthalidone (a TEN oh lole and klor THAL i done) Brand Names: Tenoretic 100, Tenoretic 50 What is atenolol and chlorthalidone? Atenolol is in a group of drugs called beta-blockers. Beta-blockers affect the heart and circulation (blood flow through arteries a more...

Budesonide Sustained-Release Capsules Budesonide Sustained-Release Capsules
Generic Name: Budesonide Sustained-Release Capsules (byoo-DESS-oh-nide) Brand Name: Entocort ECBudesonide Sustained-Release Capsules is used for:Treating mild to moderate Crohn disease and maintaining remission for up to 3 months. It may also be used for other conditions as determined by your do more...

Cataflam Cataflam
Some commonly used brand names are: In the U.S.— Actron 9 Advil 7 Advil Caplets 7 Advil, Children's 7 Aleve 14 Anaprox 14 Anaprox DS 14 Ansaid 6 Bayer Select Ibuprofen Pain Relief Formula Caplets 7 Cataflam 1 Clinoril 18 Cotylbutazone 16 Cramp End 7 Daypro 15 Dolgesic 7 Dolobid 2 EC-Napro more...

CellCept CellCept
Generic Name: mycophenolate mofetil Dosage Form: Capsules, tablets, oral suspension and intravenous injection Warning Increased susceptibility to infection and the possible development of lymphoma may result from immunosuppression. Only physicians experienced in immunosuppressive therapy and man more...

Constulose Constulose
Generic Name: lactulose (LACK too lohss) Brand Names: Cephulac, Chronulac, Constulose, Duphalac, Enulose What is Constulose (lactulose)? Lactulose is a type of sugar. It is broken down into mild acids in the colon (the end part of the intestinal tract). These acids draw water into the c more...

Dalacin C Flavored Granules Dalacin C Flavored Granules
Some commonly used brand names are: In the U.S.— Cleocin Cleocin Pediatric In Canada— Dalacin C Dalacin C Flavored Granules Dalacin C Phosphate Generic name product may be available in the U.S. Category Antibacterial, systemic Antiprotozoal Description Clindamycin (klin-d more...

NegGram NegGram
Generic Name: Nalidixic Acid Tablets (nal-ih-DIK-sik) Brand Name: NegGramNegGram is used for:Treating urinary tract infections caused by certain bacteria. NegGram is an antibacterial. It works by killing sensitive bacteria in the urinary tract by stopping the production of essential proteins n more...

Papacon Papacon
Generic Name: papaverine (pa PAV uh reen) Brand Names: Papacon, Para-Time S. R., Pavabid Plateau, Pavacot, Pavagen What is Papacon (papaverine)? Papaverine is in a class of drugs called vasodilators. Papaverine relaxes veins and arteries, which makes them wider and allows blood to pass more...